Orforglipron tablet helps maintain weight after injectable weight loss drugs

A new publication in Nature Medicine has shown that a daily tablet of orforglipron helps people with obesity or overweight maintain a significant portion of their weight loss after prior treatment with injectable glucagon-like peptide-1 receptor agonists and related incretin agents. This is an important topic because weight often returns after stopping these medications, and long-term treatment with injections is not suitable for everyone.

Orforglipron is an oral, non-peptide glucagon-like peptide-1 receptor agonist. Unlike some other oral medications in this class, it is designed as a small-molecule tablet and can be taken without strict food and water restrictions. In the US, the drug is already approved under the name Foundayo for excess weight loss and long-term weight loss maintenance in adults with obesity or overweight and at least one weight-related comorbidity.

The new ATTAIN-MAINTAIN study examined not initial weight loss but a different clinical objective: what would happen if, after 72 weeks of treatment with tirzepatide or semaglutide, people were switched to daily oral orforglipron. Participants previously enrolled in the SURMOUNT-5 study were assigned to either orforglipron once daily or placebo and then followed for 52 weeks.

The main result: switching to orforglipron allowed for the maintenance of most of the weight loss already achieved. After tirzepatide, participants on orforglipron maintained approximately 74.7% of their previous weight loss, compared to 49.2% on placebo. After semaglutide, the figure was approximately 79.3%, compared to 37.6% on placebo.

Parameter	What is known
Preparation	Orforglipron
Trade name in the USA	Foundayo
Class	Oral glucagon-like peptide-1 receptor agonist
Study	ATTAIN-MAINTAIN
Magazine	Nature Medicine
Participants	376 people
Observation	52 weeks after switching from injection therapy
DOI	10.1038/s41591-026-04386-7

Why is this work important?

Modern obesity treatments have produced powerful results: tirzepatide and semaglutide can lead to significant weight loss. However, obesity is a chronic disease, and after stopping treatment, the body often tries to regain the weight: appetite increases, energy expenditure changes, and old metabolic signals return. Therefore, the question is not only how to lose weight but also how to maintain it.

Injectable therapy is effective, but not convenient for everyone. Some patients are reluctant to take injections, others find it difficult to store medications, others find it inconvenient to travel with injectables, and others require a simpler, long-term regimen. Therefore, an oral medication that can be taken once daily potentially expands the treatment options.

The new study is interesting because it tests a transition strategy: not "one pill for everything," but "one pill as a way to maintain results after a strong injection phase." This could become a distinct model for obesity treatment: initially, more dramatic weight loss, followed by maintenance therapy to prevent weight regain.

However, this doesn't mean that all patients should automatically switch to orforglipron after injections. The study showed a benefit over placebo, but the choice of regimen depends on the patient's baseline weight, tolerability, comorbidities, drug availability, goals, and whether a weight plateau has been achieved.

Clinical question	Why is it important?
How to maintain weight after injections	After stopping the medication, the weight often returns.
Is it possible to switch to a pill?	Convenience can increase long-term adherence
Is it necessary to continue treatment for years?	Obesity often requires chronic management.
Is this transition suitable for everyone?	No, an individual assessment is required.
Is this a treatment or prevention of weight gain?	This study is about maintaining the results already achieved.

How the study was conducted

ATTAIN-MAINTAIN was a double-blind, randomized, placebo-controlled Phase 3b study. This means that participants were randomly assigned to groups; neither patients nor researchers knew who was receiving the active drug, and the comparison was made with a placebo. This design is considered a powerful way to test whether the drug is truly effective.

The study included participants who had previously completed SURMOUNT-5 and received either tirzepatide or semaglutide for 72 weeks. They were then assigned to two independent cohorts: 205 participants in the tirzepatide cohort and 171 participants in the semaglutide cohort. A total of 376 participants were enrolled in ATTAIN-MAINTAIN at 29 centers in the United States.

In cohort 1, 125 participants received orforglipron and 80 received placebo. In cohort 2, 105 participants received orforglipron and 66 received placebo. Treatment lasted for 52 weeks, after which the percentage of initial weight loss maintained was assessed.

The average age of participants was approximately 48.5 years in both cohorts. Most participants were women, and the average body weight at the start of ATTAIN-MAINTAIN was approximately 90.1 kilograms in the tirzepatide cohort and 94.4 kilograms in the semaglutide cohort.

Design element	Details
Type of study	Phase 3b, randomized, double-blind, placebo-controlled
Previous treatment	72 weeks of tirzepatide or semaglutide in SURMOUNT-5
Post-tirzepatide cohort	205 participants
Post-semaglutide cohort	171 participants
Duration of the new phase	52 weeks
Venue	29 centers in the United States

What the results showed after tirzepatide

Participants who had previously received tirzepatide and had reached a weight plateau maintained 74.7% of their previous weight loss while on orforglipron. In the placebo group, this figure was 49.2%. The difference between the groups was statistically significant, amounting to 25.5 percentage points.

In other words, after discontinuing tirzepatide, participants regained some of their weight without active maintenance therapy, while switching to orforglipron helped maintain more of the results. This is particularly important because tirzepatide typically produces significant weight loss, and even a partial loss of effect can be clinically significant.

Among participants in the tirzepatide cohort who reached a weight plateau, 43.7% of patients on orforglipron maintained at least 80% of their previous weight loss. This figure was 16.4% in the placebo group. This demonstrates that the pill not only slightly slowed weight regain but, for some people, helped maintain most of the weight loss.

When analyzing all participants in the post-tirzepatide cohort, orforglipron also showed an advantage: participants maintained approximately 74.4% of their previous weight loss, compared to 49.7% in the placebo group. This means the result was maintained not only in the narrow subgroup of those who reached a plateau, but also in the broader assessment.

After tirzepatide	Orforglipron	Placebo
Proportion of previous weight loss retained in those who reached a plateau	74.7%	49.2%
Difference vs. placebo	25.5 percentage points	-
Maintained at least 80% of previous weight loss	43.7%	16.4%
Percentage of weight loss maintained among all participants	74.4%	49.7%

What did the results show after semaglutide?

In the cohort of participants previously treated with semaglutide, the result was even more pronounced. Among those who reached a weight plateau, orforglipron helped maintain 79.3% of the previous weight loss, while placebo only maintained 37.6%. The difference was 41.7 percentage points.

This means that after discontinuing semaglutide without an active maintenance medication, weight regain was more significant. However, switching to orforglipron allowed for the maintenance of most of the achieved results. From a clinical perspective, this is especially important for patients who have achieved significant weight loss on semaglutide but, for various reasons, want to switch to oral therapy.

Among participants who reached a weight plateau after semaglutide, 55.0% of those on orforglipron maintained at least 80% of their previous weight loss. In the placebo group, this figure was only 6.9%. This demonstrates a significant difference between active maintenance therapy and treatment discontinuation.

In a larger evaluation of all participants in the semaglutide cohort, orforglipron helped maintain 85.9% of the initial weight loss, compared to 40.2% with placebo. Therefore, the authors conclude that the drug may be a useful tool for minimizing weight regain after injection therapy.

After semaglutide	Orforglipron	Placebo
Proportion of previous weight loss retained in those who reached a plateau	79.3%	37.6%
Difference vs. placebo	41.7 percentage points	-
Maintained at least 80% of previous weight loss	55.0%	6.9%
Percentage of weight loss maintained among all participants	85.9%	40.2%

Safety and tolerability

The adverse event profile in the study was generally consistent with that expected for drugs that target the glucagon-like peptide-1 receptor. The most commonly reported adverse reactions were gastrointestinal reactions: nausea, constipation, vomiting, or diarrhea. Most of these reactions were mild or moderate.

The proportion of participants discontinuing treatment due to adverse events ranged from 4.8% to 7.3% among those receiving the maximum tolerated dose of orforglipron. The overall incidence of adverse events and serious adverse events was similar between groups, supporting the conclusion of acceptable tolerability under the study conditions.

During the first 4 weeks of switching from injection therapy to orforglipron, the overall incidence of gastrointestinal adverse events, including nausea, vomiting, and diarrhea, was 10.5% in the tirzepatide cohort and 9.5% in the semaglutide cohort. The researchers note that most of these events were mild or moderate.

Importantly, the FDA-approved labeling for Foundayo includes warnings and precautions, including pancreatitis, severe gastrointestinal reactions, acute kidney injury due to fluid loss, hypoglycemia, hypersensitivity reactions, diabetic retinopathy in patients with type 2 diabetes, gallbladder disease, and the risk of aspiration during general anesthesia or deep sedation. The drug should also not be co-administered with another glucagon-like peptide-1 receptor agonist.

Security issue	What is known
Common reactions	Nausea, constipation, vomiting, diarrhea
The severity of most gastrointestinal reactions	Mild to moderate
Discontinuation due to adverse events	4.8-7.3% at maximum tolerated dose
Special warnings	Pancreatitis, severe gastrointestinal reactions, acute kidney injury, hypoglycemia, gallbladder disease
Important limitation	Do not combine with another glucagon-like peptide-1 receptor agonist

What does this change in obesity treatment?

The study's primary significance is the development of an evidence-based model for maintenance treatment after injection therapy. Until now, a frequently discussed question has been what to do for patients who have achieved significant weight loss on semaglutide or tirzepatide but are unwilling or unable to continue injections. ATTAIN-MAINTAIN demonstrates that oral orforglipron may be an option for maintaining the results.

This could shift the logic of obesity treatment toward more flexible regimens. One patient may remain on injectable therapy, another may switch to an oral form, and a third may use the oral form as a long-term maintenance strategy. However, such personalization should be based not on convenience alone, but on efficacy, tolerability, contraindications, comorbidities, and drug availability.

The regulatory context is also important: the FDA approved Foundayo on April 1, 2026, for use in conjunction with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight loss in adults who are obese or overweight with at least one weight-related comorbid condition.

At the same time, orforglipron doesn't replace the need for diet, physical activity, blood pressure, glucose, lipid management, sleep, or comorbid conditions. Like other obesity medications, it works best as part of a long-term medical strategy rather than as a stand-alone "diet pill."

Possible change in practice	What does this mean?
Switching from injections to tablets	May help maintain weight after semaglutide or tirzepatide
More options for the patient	Fewer barriers associated with injections and storage
Supportive treatment	Focus not only on losing weight, but also on maintaining it
Not a replacement for lifestyle	Diet and physical activity remain part of the indication
Medical supervision is required	It is important to consider the risks, contraindications and tolerability

Limitations of the study

The first limitation is that the participants in SURMOUNT-5 had already completed 72 weeks of successful treatment with tirzepatide or semaglutide. This is not a typical starter population of obese patients, but rather people already enrolled in a clinical trial and having achieved a significant outcome. Therefore, the findings cannot be automatically generalized to all patients starting treatment from scratch.

The second limitation is that the study compared orforglipron with placebo after discontinuing injectable therapy, not directly with continuing semaglutide or tirzepatide. Therefore, it doesn't answer the question of whether continuing the previous injectable medication or switching to an oral tablet is better. It does show that the oral tablet is better than no active maintenance therapy.

The third limitation is the 52-week follow-up period after the switch. This is an important timeframe, but obesity typically requires long-term management. Data on longer-term use, real-world practice, adherence, cost, availability, and impact on cardiovascular outcomes are needed.

The fourth limitation relates to funding and the manufacturer's involvement. The article states that the study was funded by Eli Lilly and Company, and the sponsor participated in the design, data collection, analysis, interpretation, and writing of the report. This does not invalidate the results, but it requires a transparent interpretation and independent confirmation in further studies.

Limitation	Why is it important?
Participants had already lost weight with injections.	This is not a study of initiating therapy in all patients.
The comparison was with placebo.	There is no direct answer as to whether switching is better than continuing injections.
52 weeks of observation	More long-term data is needed
The manufacturer funded the study.	Transparency and independent verification are required.
The study was conducted in the United States.	Actual availability and practices may vary in other countries.

Brief conclusion

The ATTAIN-MAINTAIN study shows that daily oral orforglipron helped maintain a significant portion of weight loss after 72 weeks of treatment with tirzepatide or semaglutide. After tirzepatide, participants on orforglipron retained approximately 75% of their previous weight loss, and after semaglutide, approximately 79%, while retention was significantly lower in the placebo groups.

The main point of this news isn't that there's an "easy pill instead of injections," but that obesity is increasingly being viewed as a chronic disease, where not only the initial weight loss phase is important, but also long-term maintenance. Orforglipron may be a convenient maintenance therapy option for some patients, but it should only be used as prescribed by a doctor, taking into account contraindications, tolerability, and the overall treatment strategy.

News source: Louis J. Aronne, Deborah B. Horn, Carel W. le Roux, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine, published May 13, 2026. DOI: 10.1038/s41591-026-04386-7.